Salvatore Nieddu

Salvatore Nieddu

Auto-generated profile, based on publicly available information

Salvatore Nieddu

Department of Life and Environmental Sciences, University of Cagliari, S.P. 8 Monserrato, Sestu Km 0.700 - I, 09042, Monserrato, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2025 in Antiviral Research
Verified
Journal Article
Open access
DZDebora Zian
Debora Zian
DIDaniela Iaconis
Daniela Iaconis
SNSimone Nenci
Simone Nenci
ACAlessandra Crusco
Alessandra Crusco
STSanjeevani Tawde
Sanjeevani Tawde
MCMariaPia Catalani
MariaPia Catalani
The COVID-19 pandemic highlighted the importance of accelerating the drug discovery process. The 3-chymotrypsin-like protease (3CLpro) is a critical enzyme in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replication process and was quickly identified as a prime target for drug development. This study leverages High-Throughput Screening (HTS) to identify novel 3CLpro inhibitors. We screened a different library of 325,000 compounds, leading to the discovery of two new chemical scaffolds with selective inhibitory activity against 3CLpro. In-silico analysis and further experimental validation, elucidated the binding modes and mechanisms of action, revealing a covalent inhibitor targeting the catalytic pocket and two allosteric inhibitors affecting the monomer/dimer equilibrium of 3CLpro. The identified compounds demonstrated significant antiviral activity in vitro, reducing SARS-CoV-2 replication in VeroE6 and Calu-3 cell lines. This study highlights the potential of combining HTS and computational approaches to accelerate the discovery of effective antiviral agents, suggesting a workflow to support the research and the design of effective therapeutic strategies.

5 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
Antonio LupiaAntonio Lupia
Antonio Lupia
SNSalvatore Nieddu
Salvatore Nieddu
LDLaura Demuru
Laura Demuru
ESErica Sanna
Erica Sanna
AOAlessia Onali
Alessia Onali
Enzo TramontanoEnzo Tramontano
Enzo Tramontano
Starting from the crystal structure of a Zika virus (ZIKV) NS2B-NS3 protease with bound allosteric inhibitor, we generated dynamic pharmacophore models derived from representative molecular dynamics (MD) conformations to capture key interaction patterns. These models guided a pharmacophore-based virtual screening of commercial libraries, including commercial compounds and approved drugs, enabling the rapid selection of virtual hit compounds. Biochemical evaluation identified several inhibitors, with the antiretroviral drug Nelfinavir emerging as the most promising compound. Nelfinavir displayed the strongest inhibition of ZIKV and West Nile virus (WNV) proteases and showed antiviral activity in cell-based assays, with EC50 values of 1.79 ± 0.01 µM on ZIKV and 3.01 ± 1.25 µM in WNV, supporting its relevance as a repositionable scaffold for modulation of ZIKV and WNV infections. The activity observed across flavivirus proteases highlights the value of targeting conserved allosteric regions. Overall, this integrated computer aided drug design (CADD) strategy demonstrates the power of dynamic, structure-based pharmacophores to uncover novel allosteric inhibitors and accelerate antiviral drug repurposing.